DIPG-20. PRE-RANDOMISATION CENTRAL REVIEW AND REAL-TIME BIOMARKERS SCREENING IN THE MULTICENTRE BIOLOGICAL MEDICINE FOR DIPG ERADICATION (BIOMEDE) TRIAL: LESSONS LEARNT FROM THE FIRST 120 BIOPSIES

INTRODUCTION: BIOMEDE is a multicentre, phase-II trial comparing efficacy of erlotinib, everolimus, and dasatinib in combination with radiotherapy, in newly diagnosed diffuse intrinsic pontine glioma (DIPG) (NCT02233049). Randomisation is based on biomarkers determined in upfront stereotactic biopsi...

詳細記述

保存先:
書誌詳細
出版年:Neuro Oncol
主要な著者: Varlet, Pascale, Debily, Marie-Anne, Teuff, Gwenael Le, Tauziede-Espariat, Arnault, Pages, Mélanie, Andreiuolo, Felipe, Lechapt-Zalcman, Emanuele, Barret, Emilie, Picot, Stephanie, Nysom, Karsten, Pravong, Sophie, Vassal, Gilles, Castel, David, Puget, Stephanie, Grill, Jacques
フォーマット: Artigo
言語:Inglês
出版事項: Oxford University Press 2018
主題:
Abstracts
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6012153/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy059.113
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料